Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches

S Ghosh, A Javia, S Shetty, D Bardoliwala… - Journal of Controlled …, 2021 - Elsevier
Triple negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) are amongst
the most aggressive forms of solid tumors. TNBC is highlighted by absence of genetic …

Clinical epigenetics settings for cancer and cardiovascular diseases: real-life applications of network medicine at the bedside

F Sarno, G Benincasa, M List, AL Barabasi… - Clinical …, 2021 - Springer
Despite impressive efforts invested in epigenetic research in the last 50 years, clinical
applications are still lacking. Only a few university hospital centers currently use epigenetic …

Network-based modeling of herb combinations in traditional Chinese medicine

Y Wang, H Yang, L Chen, M Jafari… - Briefings in …, 2021 - academic.oup.com
Traditional Chinese medicine (TCM) has been practiced for thousands of years for treating
human diseases. In comparison to modern medicine, one of the advantages of TCM is the …

DrugComb update: a more comprehensive drug sensitivity data repository and analysis portal

S Zheng, J Aldahdooh, T Shadbahr… - Nucleic acids …, 2021 - academic.oup.com
Combinatorial therapies that target multiple pathways have shown great promises for
treating complex diseases. DrugComb (https://drugcomb. org/) is a web-based portal for the …

Co‐delivery of precisely prescribed multi‐prodrug combination by an engineered nanocarrier enables efficient individualized cancer chemotherapy

Y Li, Y Jiang, Z Zheng, N Du, S Guan, W Guo… - Advanced …, 2022 - Wiley Online Library
The limited anticancer drug library and the frequent occurrence of drug resistance have
driven monotherapy‐based cancer therapy into a difficult situation. Considering the …

Anticancer drug synergy prediction in understudied tissues using transfer learning

Y Kim, S Zheng, J Tang, W Jim Zheng… - Journal of the …, 2021 - academic.oup.com
Objective Drug combination screening has advantages in identifying cancer treatment
options with higher efficacy without degradation in terms of safety. A key challenge is that the …

Charting the fragmented landscape of drug synergy

CT Meyer, DJ Wooten, CF Lopez, V Quaranta - Trends in pharmacological …, 2020 - cell.com
Even as the clinical impact of drug combinations continues to accelerate, no consensus on
how to quantify drug synergy has emerged. Rather, surveying the landscape of drug synergy …

Isoorientin attenuates doxorubicin-induced cardiac injury via the activation of MAPK, Akt, and Caspase-dependent signaling pathways

S Li, H Liu, Z Lin, Z Li, Y Chen, B Chen, L Huang, X Lin… - Phytomedicine, 2022 - Elsevier
Background Chemotherapy drugs especially anthracyclines are widely used in the treatment
of hematological malignancies and solid tumors. However, their clinical application is limited …

[HTML][HTML] Nanomaterial-assisted CRISPR gene-engineering–A hallmark for triple-negative breast cancer therapeutics advancement

J Farheen, NS Hosmane, R Zhao, Q Zhao, MZ Iqbal… - Materials Today Bio, 2022 - Elsevier
Triple-negative breast cancer (TNBC) is the most violent class of tumor and accounts for 20–
24% of total breast carcinoma, in which frequently rare mutation occurs in high frequency …

[HTML][HTML] Prospect for application of mathematical models in combination cancer treatments

J Malinzi, KB Basita, S Padidar, HA Adeola - Informatics in Medicine …, 2021 - Elsevier
The long-term efficacy of targeted therapeutics for cancer treatment can be significantly
limited by the type of therapy and development of drug resistance, inter alia. Experimental …